Trials / Active Not Recruiting
Active Not RecruitingNCT05815485
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
- Status
- Active Not Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- The University of Texas Medical Branch, Galveston · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azeliragon | 30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest). |
| DRUG | Placebo | Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest). |
Timeline
- Start date
- 2023-05-04
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2023-04-18
- Last updated
- 2025-03-03
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05815485. Inclusion in this directory is not an endorsement.